Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 6,125

Document Document Title
WO/2021/066435A1
The present invention relates to a compound for an organic electric element, an organic electric element using same, and an electronic device comprising the organic electric element. According to the present invention, an organic electri...  
WO/2021/057882A1
A compound of formula I, a method for using these compounds as an EGFR inhibitor, and a pharmaceutical composition comprising these compounds. The compound is used in the treatment, prevention or amelioration of diseases or conditions su...  
WO/2021/057832A1
Privided is a KRAS mutant protein inhibitor, a composition containing the inhibitor and the use thereof.  
WO/2021/059017A1
Provided is a heterocyclic compound that can have an antagonistic action on an NMD A receptor containing the NR2B subunit and that is expected to be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine...  
WO/2021/055630A1
The invention provides substituted, saturated and unsaturated N-heterocyclic carboxamides and related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical...  
WO/2021/021953A3
Described herein are small molecule agonists of dopamine receptor D1 that inhibit YAP/TAZ, compositions, and methods of using these compounds and compositions. The methods of using such compounds in the treatment of conditions, diseases,...  
WO/2021/049654A1
An organic electroluminescent element (1) which comprises a positive electrode (3), a negative electrode (4), a first light emitting layer (51) and a second light emitting layer (52) that is arranged between the first light emitting laye...  
WO/2021/029158A1
The purpose of the present invention is to provide: a sulfonamide compound which has a high decomposition rate in response to near-ultraviolet rays and which generates a superacid bis-sulfonamide, and which is highly soluble in a resist ...  
WO/2021/029914A1
The present invention relates to opiate derived compositions and their antagonists useful in therapeutic areas associated with opioid receptor modulation. A 3-hexadienoate modification of the opioids is formulated to improve opiates' eng...  
WO/2021/028810A1
The present invention relates to certain compounds, their use in therapy, as well as to pharmaceutical compositions including said compounds. Specifically, the invention relates to certain compounds and pharmaceutical compositions includ...  
WO/2021/026380A1
Provided herein are compounds that are useful in the treatment of pain in a subject. Also provided herein is a pharmaceutical composition comprising compounds or pharmaceutically acceptable salts thereof, and a pharmaceutically acceptabl...  
WO/2021/026378A1
Provided herein are compounds that are useful in the treatment of pain in a subject. Also provided herein is a pharmaceutical composition comprising compounds or pharmaceutically acceptable salts thereof, and a pharmaceutically acceptabl...  
WO/2021/026098A1
Amide compounds of formula (I): and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of Kinesin Motor Protein KIF18A, suc...  
WO/2021/026377A1
Provided herein are compounds that are useful in the treatment of pain in a subject. Also provided herein is a pharmaceutical composition comprising compounds or pharmaceutically acceptable salts thereof, and a pharmaceutically acceptabl...  
WO/2021/026375A1
Provided herein are compounds that are useful in the treatment of pain in a subject. Also provided herein is a pharmaceutical composition comprising compounds or pharmaceutically acceptable salts thereof, and a pharmaceutically acceptabl...  
WO/2021/024925A1
The present invention aims to provide: a chemically amplified positive photosensitive resin composition that contains an acid generator having excellent solvent solubility and can readily form a resist pattern having excellent mask linea...  
WO/2021/021953A2
Described herein are small molecule agonists of dopamine receptor D1 that inhibit YAP/TAZ, compositions, and methods of using these compounds and compositions.  
WO/2021/009232A1
The present invention relates to compounds of Formula (I), (I) wherein R1, R2, R3 and R4 are as defined herein. The invention further relates to herbicidal compositions which comprise a compound of Formula (I), to their use for controlli...  
WO/2021/009229A1
The present invention relates to compounds of Formula (I), (I) wherein R1, R2, R3,W, Y, Z & G are as defined herein. The invention further relates to herbicidal compositions which comprise a compound of Formula (I), to their use for cont...  
WO/2021/009048A1
The present invention relates to compounds of Formula (I), wherein R1, R2, R3, R4 and G are as defined herein. The invention further relates to herbicidal compositions which comprise a compound of Formula (I), to their use for controllin...  
WO/2021/007146A1
Provided herein are methods of administering estrogen receptor antagonists for use in treatment of cancer. The antagonists (such as a hexahydro pyrido[3,4-b]indole, AZD9496, RAD-1901, ARN-810, endoxifen, or fulvestrant) may be an inhibit...  
WO/2020/261021A1
Described are polymerizable fused tricyclic compounds of formula I: wherein R1, R2, R3, m, n, t, and rings B, C, and D are as defined herein. The compounds absorb various wavelengths of ultraviolet and/or visible light (such as high ener...  
WO/2020/263822A1
The invention provides a series of conformationally stable and selective, irreversible kinase inhibitors, and methods of using the kinase inhibitors. The effect of atropisomerism on kinase selectivity was assessed, finding improved selec...  
WO/2020/010143A8
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein, useful to tre...  
WO/2020/257734A1
The disclosure relates, in certain aspects, to the discovery of compounds that can be used to inhibit β-lactamases, such as but not limited to OXA enzymes, such as but not limited to OXA-48. In certain embodiments, these compounds can b...  
WO/2020/254507A1
Compounds of general Formula (I) wherein the elements A, L, R1 and R2 have a defined meaning, and their medical and non-medical use.  
WO/2020/249079A1
A SHP2 phosphatase allosteric inhibitor and a drug containing said inhibitor, the SHP2 phosphatase allosteric inhibitor having the structure shown in formula (I), and the use of an optical isomer compound of the SHP2 phosphatase alloster...  
WO/2020/243224A1
The present invention relates to novel combinations. The invention also relates to such combinations for use as pharmaceuticals, for instance in the treatment of bacterial diseases, including diseased caused by pathogenic mycobacteria su...  
WO/2020/242051A1
Disclosed are: a compound; a composition comprising the compound; and a photodynamic therapy method for inactivating or killing tumor cells using the composition.  
WO/2020/234276A1
The present invention provides compounds of formula (Id) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising comp...  
WO/2020/234273A1
The present invention relates to a new process for manufacturing (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]diox olo[4',5':5,6]benzo[1,2-g]quinoline with formula (Ib), (4aR,10aR)-1-Propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[...  
WO/2020/234277A1
The present invention provides compounds of formula (Id) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising comp...  
WO/2020/221570A1
The present invention relates to a compound, and to an organic semiconductor layer comprising this compound, suitable for use as an organic semiconductor layer for electronic devices, and a method of manufacturing the same, wherein the c...  
WO/2020/223715A1
In one aspect, the disclosure relates to compounds useful to regulate, limit, or inhibit the expression of AVIL (advillin), methods of making same, pharmaceutical compositions comprising same, and methods of treating disorders associated...  
WO/2020/223136A1
The present disclosure relates to compounds of formula (I) that are useful as modulators of 7α nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly ...  
WO/2020/212408A1
The present invention relates to an organic semiconducting material comprising a compound comprising at least one dibenzo [c,h) acridine group and at least one CN-group, organic electronic devices comprising the same and display devices ...  
WO/2020/186961A1
Disclosed in the present invention are a bulleyaconitine D crystal and a preparation method therefor. Figure 1 shows an X-ray powder diffraction spectrum of the crystal according to the present invention, the spectrum being measured with...  
WO/2020/186960A1
A bulleyaconitine A crystalline form C, and a preparation method therefor. An X-ray powder diffraction spectrum of the crystalline obtained by measurement using a Cu-Kα ray is as shown in fig. 1. The preparation method therefor comprise...  
WO/2020/186962A1
Provided is a crystal form E of bulleyaconitine A and a preparation method for the crystal form E of bulleyaconitine A. An X-ray powder diffraction spectrum of the crystal form measured by Cu-K α-ray is as shown in FIG. 1. The crystal f...  
WO/2020/186963A1
Crystal form G of bulleyaconitine A and a preparation method therefor. Crystal form G of bulleyaconitine A was prepared by adding bulleyaconitine A to a mixed solution of methanoic acid and n-heptane and dissolving, stirring at a low tem...  
WO/2020/184670A1
The present invention relates to a method for monodeuterated lower alkylating an amine moiety of a compound which contains an amine that is protected by an aralkyl group, wherein a monodeuterated lower alkyl is introduced into the amine ...  
WO/2020/184649A1
Provided as a material able to produce an optical member, such as a lens having a high light transmittance, is a solvate of a compound represented by general formula 1, wherein the solvent contains a nitrogen atom-containing organic comp...  
WO/2020/169648A1
The present invention relates to compounds of Formula (I), 5 wherein R1, R2, R3, R4 and G are as defined herein. The invention further relates to herbicidal compositions which comprise a compound of Formula (I), to their use for controll...  
WO/2020/165233A1
The present invention relates to compounds of Formula (I), (I) wherein R1, R2, R3, R4 and G are as defined herein. The invention further relates to herbicidal compositions which comprise a compound of Formula (I), to their use for contro...  
WO/2020/165102A1
The present invention relates to compounds of Formula (I), wherein R1, R2, R3, R4 and G are as defined herein. The invention further relates to herbicidal compositions which comprise a compound of Formula (I), to their use for controllin...  
WO/2020/160134A1
Disclosed herein are certain acetamido derivatives that are DNA Polymerase Theta (Polθ) inhibitors of Formula (I). Also, disclosed are pharmaceutical compositions comprising such compounds and methods of treating diseases treatable by i...  
WO/2020/124688A9
Provided in the present invention are full-spectrum high-brightness and high-stability fluorescent dyes, the dyes being one or several of the following mixed according to any ratio: 4-amido substituted naphthalimide dye, bisalkoxy substi...  
WO/2020/139971A3
The present disclosure provides methods of preparing Compound of Formula (I), solid state forms of the same and compositions comprising the same. Also disclosed herein are methods of preparing a diacetate salt of Compound of Formula (I) ...  
WO/2019/226678A3
Disclosed herein are compound capable of exploiting non-bonding electron densities, for example, cationic open-shell, pi-conjugated bisphenalenyls wherein intermolecular covalent bonding interactions can occur in multiple dimensions. Fur...  
WO/2020/143198A1
Ketamine derivatives and pharmaceutical compositons thereof are disclosed. When administered orally the ketamine derivatives provide increased bioavailability of ketamine in the systemic circulation. The ketamine derivatives can be used ...  

Matches 1 - 50 out of 6,125